Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis.

Nikolaos PerakakisStefan R BornsteinAndreas L BirkenfeldAndreas LinkermannMünevver DemirStefan D AnkerGerasimos FilippatosBertram PittEllen BurgessLuis M RuilopePeter KolkhofRobert LawatscheckCharlie ScottGeorge L Bakrisnull null

Published in: Diabetes, obesity & metabolism (2023)

Finerenone has neutral effects on liver parameters in patients with chronic kidney disease and type 2 diabetes. Finerenone showed robust and consistent kidney benefits in patients with altered liver tests, and profound cardiovascular benefits even in patients with higher FIB-4 scores who were at high risk of developing cardiovascular complications.

Keyphrases

type diabetes
chronic kidney disease
insulin resistance
cardiovascular disease
high fat diet
clinical trial
risk factors
glycemic control
autism spectrum disorder
open label
phase iii